Agilent is investing $80 million in our client Lasergen, an emerging biotechnology company with innovative next-generation sequencing (NGS) technology. The two companies will collaborate on building a NGS solutions workflow for clinical applications, based on Lasergen’s Lightning Terminators™ sequencing chemistry.
This recent investment showcases the trend toward new players and innovative technology in the NGS space, particularly as the technology moves to more routine clinical use.
Lasergen’s relationship with Agilent is another example of how Popper and Company helps companies create transformative business partnerships.
Tags: biotech, diagnostics, digital health, sequencing
Posted in Diagnostics, Our Views | No Comments »
Danaher Corporation (NYSE:DHR) announced today (see San Francisco Chronicle story here) that it has entered into an agreement with Beckman Coulter, Inc. (NYSE: BEC) to acquire Beckman for approximately $6.8 billion. When the acquisition is complete, Beckman will become part of Danaher’s Life Sciences and Diagnostics business segment.
This is yet another example of the diagnostics landscape’s rapid upheaval in which different players will clearly be dominating and leading the industry.
The diagnostics industry shake up is in full swing: As we wrote recently, sequencing technology (one critical part of the Dx space) is changing at an earth-shattering speed and today’s announcement is evidence of what is happening on the market level. Need more evidence? Check out this post by Xconomy’s Luke Timmerman on “diagnostics warming up.”
Read the rest of this entry »
Tags: beckman coulter, biotech, Caroline Popper, danaher corporation, devices, FDA, life sciences, sequencing
Posted in Our Views | No Comments »